Morgan Stanley’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $430M | Sell |
8,471,263
-399,453
| -5% | -$18.6M | 0.03% | 588 |
|
|
2025
Q4 | $262M | Sell |
8,870,716
-1,091,516
| -11% | -$29.7M | 0.02% | 806 |
|
|
2025
Q3 | $257M | Buy |
9,962,232
+1,858,694
| +23% | +$51.8M | 0.02% | 787 |
|
|
2025
Q2 | $224M | Buy |
8,103,538
+665,133
| +9% | +$17.5M | 0.01% | 823 |
|
|
2025
Q1 | $211M | Buy |
7,438,405
+3,190,707
| +75% | +$113M | 0.02% | 812 |
|
|
2024
Q4 | $177M | Buy |
4,247,698
+738,609
| +21% | +$35.3M | 0.01% | 902 |
|
|
2024
Q3 | $235M | Sell |
3,509,089
-1,497,431
| -30% | -$137M | 0.02% | 744 |
|
|
2024
Q2 | $595M | Sell |
5,006,520
-487,445
| -9% | -$61.7M | 0.05% | 378 |
|
|
2024
Q1 | $585M | Sell |
5,493,965
-3,284,251
| -37% | -$331M | 0.05% | 383 |
|
|
2023
Q4 | $873M | Buy |
8,778,216
+3,466,202
| +65% | +$292M | 0.04% | 451 |
|
|
2023
Q3 | $549M | Sell |
5,312,014
-505,071
| -9% | -$56.3M | 0.06% | 328 |
|
|
2023
Q2 | $707M | Buy |
5,817,085
+866,512
| +18% | +$116M | 0.07% | 265 |
|
|
2023
Q1 | $760M | Buy |
4,950,573
+763,220
| +18% | +$126M | 0.08% | 238 |
|
|
2022
Q4 | $752M | Buy |
4,187,353
+670,284
| +19% | +$110M | 0.09% | 231 |
|
|
2022
Q3 | $416M | Buy |
3,517,069
+35,547
| +1% | +$5.39M | 0.06% | 330 |
|
|
2022
Q2 | $497M | Buy |
3,481,522
+570,718
| +20% | +$81.6M | 0.06% | 295 |
|
|
2022
Q1 | $501M | Sell |
2,910,804
-1,930,052
| -40% | -$325M | 0.07% | 266 |
|
|
2021
Q4 | $1.23B | Sell |
4,840,856
-820,531
| -14% | -$240M | 0.15% | 146 |
|
|
2021
Q3 | $2.18B | Sell |
5,661,387
-1,760,110
| -24% | -$649M | 0.29% | 72 |
|
|
2021
Q2 | $1.74B | Sell |
7,421,497
-801,291
| -10% | -$143M | 0.23% | 101 |
|
|
2021
Q1 | $1.08B | Buy |
8,222,788
+2,427,704
| +42% | +$352M | 0.16% | 143 |
|
|
2020
Q4 | $605M | Buy |
5,795,084
+761,697
| +15% | +$77.1M | 0.09% | 199 |
|
|
2020
Q3 | $356M | Sell |
5,033,387
-1,350,738
| -21% | -$94.2M | 0.07% | 252 |
|
|
2020
Q2 | $410M | Buy |
6,384,125
+899,098
| +16% | +$49.2M | 0.09% | 202 |
|
|
2020
Q1 | $164M | Buy |
5,485,027
+675,919
| +14% | +$15.6M | 0.04% | 356 |
|
|
2019
Q4 | $94.1M | Buy |
4,809,108
+303,041
| +7% | +$5.38M | 0.02% | 637 |
|
|
2019
Q3 | $71.7M | Sell |
4,506,067
-228,975
| -5% | -$3.38M | 0.02% | 684 |
|
|
2019
Q2 | $69.3M | Buy |
4,735,042
+1,321,777
| +39% | +$28.4M | 0.02% | 696 |
|
|
2019
Q1 | $69.5M | Buy |
3,413,265
+1,260,145
| +59% | +$23.4M | 0.02% | 675 |
|
|
2018
Q4 | $32.9M | Buy |
+2,153,120
| New | +$35.4M | 0.01% | 1060 |
|
Other funds holding MRNA
VCM
VPM
TP
Morgan Stanley's MRNA Position: Q1 2026 in Review
Morgan Stanley reduced its Moderna (MRNA) stake by 4.5% in Q1 2026, selling an estimated $18.6M and leaving 8,471,263 shares worth $430M. The position accounts for 0.03% of the portfolio, ranked #588.
Morgan Stanley first reported a position in MRNA in Q4 2018 and has held it in 30 quarters since. The position peaked at $2.18B in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.
- Morgan Stanley held 8,471,263 shares of Moderna worth $430M as of Q1 2026.
- Morgan Stanley sold 399,453 Moderna shares in Q1 2026, an estimated $18.6M.
- Moderna made up 0.03% of Morgan Stanley's portfolio in Q1 2026, its #588 holding.
- Morgan Stanley first reported a position in Moderna in Q4 2018 and has held it in 30 quarters since.
- Morgan Stanley's Moderna position peaked at $2.18B in Q3 2021.
- 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.